3,0
22. Sept. 2022
Aktueller Mitarbeiter, mehr als 3 Jahre
Raleigh, NC
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Lack of strategy for long term affects non management roles in the short term Bonuses if you are G13 or above pay grades do not align with buckets of money available for each business so that can be good or bad Remote work possible Continuing education used to be possible.
Kontras
Instability reigns between Diagnostics and Drug Development. No merit pay starting 2022 Bonuses paid to those G13 and above Lack of cohesiveness and team work between varying lines of business Management training needs to focus on day to day management, not just taking a crash course on LearningPath Too focused on "popular" causes and differences between people instead of focusing on our common goals and similarities